title: [X-ray guided endovascular occlusion of prostate arteries--alternative innovative method of treatment for patients with large prostatic adenomas].
abstract: The choice of method of surgical treatment of prostatic adenoma depends on the size of prostate, but often it can be limited to the patients with anesthesia risk or somatic risk. The article presents an alternative method of treatment of large prostatic adenomas--x-ray guided endovascular occlusion of prostate arteries, through which 38 patients were treated. Effectiveness of x-ray guided endovascular occlusion was evaluated in comparison to open prostatectomy (40 patients) and the administration of 5alpha-reductase inhibitor (43 patients). In the first two months after surgery, significant reduction in prostate volume and increased urinary flow rate was observed. Length of stay in the group of x-ray guided endovascular occlusion of prostate arteries was significantly less than in the group of open prostatectomy--2.3 days versus 19.7, respectively (P < 0.001). Variants of use of x-ray guided endovascular occlusion of prostate arteries in clinical practice are presented.
authors.forename: D G
authors.initials: DG
authors.lastname: Kurbatov
authors.forename: S A
authors.initials: SA
authors.lastname: Dubskiĭ
authors.forename: I I
authors.initials: II
authors.lastname: sitkin
authors.forename: A E
authors.initials: AE
authors.lastname: Lepetukhin
mesh_terms: D058891:5-alpha Reductase Inhibitors / Q000008:administration & dosage*; D000368:Aged; D001158:Arteries / Q000503:physiopathology / Q000601:surgery; D057510:Endovascular Procedures / Q000295:instrumentation / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000098:blood supply / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery; D011468:Prostatectomy / Q000295:instrumentation / Q000379:methods; D011470:Prostatic Hyperplasia / Q000000981:diagnostic imaging / Q000503:physiopathology / Q000601:surgery; D011859:Radiography
chemical_list: D058891:5-alpha Reductase Inhibitors